Apogee Therapeutics (APGE) Share-based Compensation (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Share-based Compensation data on file, last reported at $17.2 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $17.2 million, up 54.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.3 million (up 72.79% YoY), and the FY2025 annual result was $46.3 million, up 98.34% from the prior year.
• Share-based Compensation climbed to $17.2 million in Q1 2026 per APGE's latest filing, from $11.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $17.2 million in Q1 2026 and troughed at $1.1 million in Q2 2023.
• A 4-year average of $7.1 million and a median of $5.8 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation soared 411.95% in 2024, then jumped 54.19% in 2026.
• A 4-year view of Share-based Compensation shows it stood at $2.2 million in 2023, then soared by 244.14% to $7.6 million in 2024, then soared by 56.79% to $11.9 million in 2025, then soared by 43.8% to $17.2 million in 2026.
• Business Quant data shows APGE's Share-based Compensation at $17.2 million in Q1 2026, $11.9 million in Q4 2025, and $11.9 million in Q3 2025.